Breaking Finance News

Bank of America Corporation downgraded Cardiovascular Systems Inc (NASDAQ:CSII) to Underperform in a report released today.

Just yesterday Cardiovascular Systems Inc (NASDAQ:CSII) traded -1.10% lower at $31.80. Cardiovascular Systems Inc’s 50-day moving average is $30.19 and its 200-day moving average is $30.13. The last closing price is up 1.08% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 307,141 shares of CSII traded hands, up from an average trading volume of 237,641

Bank of America Corporation has downgraded Cardiovascular Systems Inc (NASDAQ:CSII) to Underperform in a report released on 06/21/2017.

Recent Performance Chart

Cardiovascular Systems Inc (NASDAQ:CSII)

Cardiovascular Systems Inc has 52 week low of $21.29 and a 52 week high of $33.11 and has a market capitalization of $0.

In addition to Bank of America Corporation reporting its stock price target, a total of 6 brokers have issued a report on the stock. The consensus target price is $16.50 with 2 brokerages rating the company a strong buy, three brokerages rating the company a buy, one brokerage rating the company a hold, one equity analyst rating the company a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About Cardiovascular Systems Inc (NASDAQ:CSII)

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.